You are here
CERID Bibliography
Export 61 results:
Author Title Type [ Year] Filters: Keyword is Herpesvirus 2, Human [Clear All Filters]
Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. J Virol. 2014 ;88(9):4921-31.
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature. 2013 ;497(7450):494-7.
An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J Virol. 2012 ;86(19):10587-96.
. Peripheral blood CD4 T-cell and plasmacytoid dendritic cell (pDC) reactivity to herpes simplex virus 2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes. J Virol. 2012 ;86(18):9952-63.
. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012 ;379(9816):641-7.
. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol. 2012 ;93(Pt 6):1305-15.
. HSV-2: in pursuit of a vaccine. J Clin Invest. 2011 ;121(12):4600-9.
. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine. 2011 ;29(47):8520-9.
. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex Transm Infect. 2010 ;86(3):202-6.
. Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. J Clin Immunol. 2010 ;30(5):703-22.
. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine. 2010 ;28(47):7483-91.
. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release. 2010 ;148(3):327-33.
Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010 ;107(44):18973-8.
. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J Immunol. 2010 ;184(6):3063-71.
. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers. Antivir Ther. 2010 ;15(8):1141-9.
. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol. 2009 ;83(23):12559-68.
. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol. 2009 ;90(Pt 5):1153-63.
Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med. 2008 ;59:381-95.
. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis. 2008 ;35(4):383-6.
. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol. 2008 ;15(5):773-82.
. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol. 2008 ;15(11):1638-43.
. . .